Cellular testing for pharmaceuticals – how to discover that technology’s commercial potential What’s the future of technologies for screening cells? Now discover those technological and commercial predictions from 2015. Stay ahead with this definitive market data, benefiting your influence. For those medical tests, you can explore sales results, R&D, opportunities and revenue forecasts.
This new report by Visiongain shows you what’s possible for cell-based assays and related applications to aid drug discovery and development. Those R&D tools change pharma, opening new possibilities. Find out how, discovering predicted trends, progress and gains.
Use of cell lines in bioassays becomes more important. Read on to explore cell assaying products and services for medicine, seeing how high their revenues can go.
Forecasts and other analysis showing potential revenues from those bioassays Our study’s purpose is forecasting cell testing sales to 2025 at overall world, submarket and national level. Our work assesses those technologies for research and development, showing where the money and potential gains will be.
Avoid struggling to find information on bioassays. Besides revenue predictions, our new analysis shows recent results, growth rates and market shares.
The new survey provides you with 63 tables, 40 charts and three interviews with companies. This study will help your research, analyses and decisions now, and also benefit your authority and reputation for technological and commercial insight.
And the following sections explain how our investigation helps your work.
Predictions for the cellular assays market and its segments – assess sales prospects What potential does that biomedical industry hold? And what secrets underpin its progress? Discover in our report overall world revenue to 2025 for cell assays, with discussions.
Also find individual revenue predictions from 2015 for submarkets there, at world level:
• Products • Services.
And get further revenue breakdown, from 2015, by application:
You can assess revenue expansion and where you could gain. Those uses include toxicity testing. See what’s possible and investigate competition among developers and producers of cellular tests. You will be able to explore products, services, emerging technologies and rising sales.
Our work also divides the overall world market into geographical revenue predictions.
Sales in leading national markets – what demand for medical cell assaying? Our analyses also shows you individual revenue forecasts to 2025 for 11 leading countries:
• United States (US) • Japan • Germany, France, United Kingdom (UK), Italy and Spain (EU5 countries), also with an overall European Union prediction • Brazil, Russia, India and China (BRIC nations).
There you will find the countries with the highest revenues, demand and potential increases in cell assay use and sales. And you can further understand the competitors, needs and opportunities. That way you will explore the trends, progress and potentials, discovering what gains the future potentially holds.
Also how do events, challenges and advances in technology affect that bioassays sector? Our study explains by discussing progress, policies and trends influencing cellular assaying, helping you stay ahead in knowledge.
Forces affecting developers and producers of those drug discovery and development tools The report explains the issues, operations and events affecting the market from 2015. The forces influencing companies developing, making and selling those systems include:
• Uses in drug discovery, validating targets and lead profiling – including 2D and 3D bioassaying systems • Platforms using high throughput screening (HTS) for improved testing efficiency • Stem cells (inc. IPSCs) to extend molecular screening, esp. in toxicology studies, and other cell lines for pharma in vitro assays • Systems using biochemical assays, GPCRs (G-protein-coupled receptors) and label-free methods • Applications in developing biological drugs • Contract and clinical research organisations (CROs) in that early-stage drug development.
And you can explore the following trends and influences, among others:
• Lead identification, target validation, primary, secondary and ADME screening • Cell assaying equipment, kits, consumables and disposables • Detection technology, microplate readers, microfluidics and flow cytometry, inc. assay miniaturisation and automation • Multiplexing to improve efficiency in studying biological materials • Cell viability and mitochondrial function assays in biomedical research • High content screening (HCS) – optimising processes, increasing R&D pipeline efficiencies.
You can explore what progress, trends and prospects in those bioassays mean. And you will discover what benefits and what restricts participants in that industry, affecting its results.
Cell technologies for medical product development – top companies and 2018 market value What does the future hold? Our study predicts the cell based assays world market will reach $5.5bn in 2018.
Also, from 2015, outsourcing of cell-based assay processes will increase. Pharmaceutical clients and CROs will benefit. In our study, you will see how, discovering the potential.
And our new report examines activities of many companies, including these:
• Thermo Fisher Scientific • PerkinElmer • DiscoveRx • GE Healthcare • ProQinase • Charles River Laboratories • BD (Becton, Dickinson and Company).
You will find profiles of 18 prominent, rising and emerging companies. And you will see interviews with Cell Assay Innovations (CAI), Molecular Devices and CYTOO. Our survey explores issues affecting that industry’s present and future.
Cell and tissue-based screening holds great potential. From this decade onwards, the market offers many opportunities. See where they exist and how that industry can perform.
Ways Cell-Based Assays: World Industry and Market Prospects 2015-2025 helps In particular, our new investigation gives you this knowledge to benefit your research, analyses and planning:
• Revenues for cellular assays, to 2025, at world level and for five submarkets – explore the prospects for design, production, sales, marketing, demand and spending
• Forecasts, to 2025, for 11 countries in the Americas, Europe and Asia – assess the developed and developing national markets for demand and predicted revenues
• Prospects for established firms, rising companies and new entrants – examine the product and service portfolios, results, strategies and outlooks for success
• Analyses of what stimulates and restrains that industry’s participants – investigate the challenges, strengths and competition affecting organisations’ actions
• Interviews with authorities in that field – discover what participants from the industry think, say and do, helping you stay ahead in business knowledge.
Information found nowhere else, benefiting your insight, work and influence Our study, produced in-house by our UK-based analysts, provides independent knowledge. You will gain competitive intelligence found only in our report, finding where the progress and business prospects exist.
With our definitive market data you’re less likely to fall behind in information or miss an opportunity. See how you could save time and effort. And, through your choice, benefit your plans, decisions and authority, helping you gain competitive advantages.
Data to help your knowledge of pharma R&D – benefit from our study now Our new analysis is for everyone investigating pharmaceutical research and development. For cellular assaying systems, you can explore the trends, results and revenue forecasts. So avoid missing out – please get that report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Cell-Based Assays: Overview 1.2 Cell-Based Assays Market Segmentation 1.3 Why You Should Read This Report 1.4 How this Report Delivers 1.5 Questions Answered by this Report 1.6 Who is this Report for? 1.7 Research and Analysis Methods 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Reports 1.10 About Visiongain
2. Introduction to Cell-Based Assays and Applications 2.1 Cost of New Drug Discovery and Development Reaches $2.6bn - Companies Constantly Looking for Increased Efficiencies 2.2 Drug Discovery Approaches- Target-Based and Phenotype-Based Discovery 2.3 Drug Screening Assays 2.4 Animal Models: In Vivo Conditions, but Results May Not Be Transferable to People 2.5 Biochemical Assays and their Advantages over Animal Models 2.5.1 Applications of Biochemical Assays 2.5.2 Lead Identification and Toxicity Testing 2.6 Cell-Based Assays and their Advantages 2.7 2D vs 3D Cell-Based Assays 2.8 The Different Assay Detection Methods and Technologies 2.9 Cells Used in Cell-Based Assays 2.9.1 Immortalised Cell Lines - Convenient but not Truly Representative of Normal Human Cells 2.9.2 Primary Cells: Closer to the In Vivo Environment, but Short Supply 2.9.3 Stem Cells: Potential to Overcome Limitations of Primary Cells and Immortalised Cell Lines 2.10 Uses for Cell-Based Assays in Drug Discovery and Development 2.10.1 Target Validation 2.10.2 Primary Screening 2.10.3 Secondary Screening 2.10.4 ADME Screening 2.10.5 High Throughput Screening: Greatly Increases Efficiency
3. World Cell-Based Assays Market, 2015-2025 3.1 Global Cell-Based Assays Market Forecast 2015-2025 3.2 Drivers for the Cell-Based Assays Market 3.3 Restraints for the Cell-Based Assays Market 3.4 Cell-Based Assays: Market Segments - Products and Services 3.5 Cell-Based Assays, Market Segments: Products Forecast 2015-2025 3.5.1 The Three Main Categories of Cell-Based Assay Products 3.5.1.1 Equipment Needed to Conduct Cell-Based Assays 3.5.1.2 Disposables Necessary to Perform Cell-Based Assays 3.5.1.3 Consumables Forming the Basis of Cell-Based Assays 3.6 Cell-Based Assays Market Segments: Services 3.6.1 Cell-Based Assays Market Segments: Services Forecast 2015-2025 3.7 Cell-Based Assays Market: Applications Forecasts 2015-2025 3.7.1 Drug Discovery Segment 3.7.2 ADME (Absorption, Distribution, Metabolism, Excretion) Segment 3.7.3 Basic Research Segment
4. Leading National Markets for Cell-Based Assays, 2015-2025 4.1 Regional Breakdown of the Global Cell-Based Assays Market, 2014 and 2025 4.2 Global Cell-Based Assays Market: Regional Forecast 2015-2025 4.3 The US Cell-Based Assays Revenue Forecast to 2025 4.4 European Union (EU) Cell-Based Assays Market 2015-2025 4.4.1 IMI’s Pan-European Drug Discovery Platform Holds Much Promise 4.4.2 EU Market: National Breakdown, 2014 and 2025 4.4.3 EU Market: Main National Forecasts 2015-2025 4.4.4 German Cell-Based Assay Revenue Forecast to 2025 4.4.5 French Cell-Based Assays Revenue Forecast to 2025 4.4.6 UK Cell-Based Assays Revenue Forecast to 2025 4.4.7 Spanish Cell-Based Assays Revenue Forecast to 2025 4.4.8 Italian Cell-Based Assays Revenue Forecast to 2025 4.5 Japanese Cell-Based Assays Revenue Forecast to 2025 4.6 BRIC Nations (Brazil, Russia, India, China) Cell-Based Assays Market 4.6.1 BRIC Countries: National Breakdown 2014 and 2015 4.6.2 BRIC Countries: National Forecasts 2015-2025 4.6.3 Chinese Cell-Based Assay Revenue Forecast to 2025 4.6.4 Indian Cell-Based Assays Revenue Forecast to 2025 4.6.5 Russian Cell-Based Assays Revenue Forecast to 2025 4.6.6 Brazilian Cell-Based Assays Revenue Forecast to 2025
5. Companies in the Cell-Based Assays Market: Product Suppliers, 2015 5.1 Thermo Fisher Scientific 5.1.1 Cell-Based Assay Technologies under the Life Technologies Business Unit - Over 300 Products Offered 5.1.2 Also Offers Custom Assays, Related Products and HCA Products 5.2 DiscoveRx 5.2.1 PathHunter Technology 5.2.2 Other Assay Platforms and Drug Discovery Services 5.3 PerkinElmer 5.3.1 AlphaScreen Technology 5.3.2 DELFIA TRF Assays 5.3.3 Label-Free Cellular Assay Detection, and the Opera System 5.4 BD (Becton, Dickinson and Company) 5.4.1 Cell-Based Assays Through BD Life Sciences 5.5 InSphero 5.5.1 GravityPLUS- Leading Solution for 3D Cell-Based Assays 5.6 Biocroi 5.6.1 The Technology Behind and the Advantages of Happy Cell ASM and its 3D Cell Culture 5.7 GE Healthcare 5.7.1 Cell-Based Assays Through GE Healthcare Life Sciences 5.8 Molecular Devices 5.8.1 Cell-Based Assay Products Include SpectraMax Microplate Readers and FLIPR Tetra System 5.9 Promega 5.9.1 Assays Range from Cell Viability Assays to Mitochondrial Function Assays 5.10 BioVision 5.10.1 Cell-Based Assays Include the EZCell Platform and a Cholesterol Detection Kit
6. Companies in the Cell-Based Assays Market: CROs and Service Providers, 2015 6.1 Fluofarma 6.1.1 Over 100 Cell-Based Assays, and Partnership with Harlan 6.2 CYTOO 6.2.1 Cell Micropatterning to Eliminate Trade-Off between Quantity and Quality? 6.2.2 Cell-Based Assays for Muscular Atrophy / Hypertrophy and Anti-Cancer Drug Profiling 6.3 Cell Assay Innovations (CAI) 6.3.1 ClariCELL Technology 6.4 ProQinase 6.4.1 Various Cell-Based Assays for Characterising Anti-Cancer Compounds 6.5 Charles River Laboratories 6.5.1 PhenoFocus – Portfolio of over 100 Primary Cell-Based Assays 6.6 SGS 6.6.1 Offers a Range of Services, Including 3D Cell-Based Assays 6.7 Pharmaceutical Product Development (PPD) 6.8 Marin Biologic Laboratories
7. Cell-Based Assays Technology, Trends and Future Outlook 7.1 Stem Cells: Vast Potential 7.1.1 The Benefits of using Stem Cells in Cell-Based Assays 7.1.2 IPSCs: An Uncontroversial and Abundant Source 7.1.3 Companies Providing Stem Cell-Based Assays 7.2 Toxicity Testing: Important Field for Cell-Based Assays 7.3 3D Systems: The Advantages of these Next Generation Cell Systems 7.3.1 Complexity of 3D Systems is a Challenge, but More and More are Gradually Reaching the Market 7.4 Increasing Outsourcing of Cell-Based Assays 7.5 Label-Free Technology 7.6 GPCRs: A Common Drug and Drug Discovery Target 7.6.1 GPCRs in Cell-Based Assays 7.6.2 Allosteric GPCRs 7.7 Increasing Miniaturisation and Automation 7.7.1 Advantages of Miniaturisation 7.7.2 Advantages of Automation 7.8 Microfluidics- Set to be a Trend 7.8.1 Can Mimic the In Vivo Environment 7.8.2 The Potential and the Challenges 7.9 Multiplexing: Improves Efficiency of Cell-Based Assays 7.9.1 Advantages will Drive Growth 7.10 High Content Screening: A Well Established Tool 7.10.1 The Future for HCS: Will Continue to Expand, Still Room for Innovation 7.11 Cell-Based Assays in Biologics Development
8. Qualitative Analysis of the Cell-Based Assays Market, 2015 8.1 SWOT Analysis of the Cell-Based Assays Market 8.1.1 Strengths Within the Cell-Based Assays Market 8.1.2 Weaknesses Within the Cell-Based Assays Market 8.1.3 Opportunities for the Cell-Based Assays Market 8.1.4 Threats to the Cell-Based Assays Market 8.2 STEP Analysis of the Cell-Based Assays Market 8.2.1 Social Factors 8.2.2 Technological Factors 8.2.3 Economic Factors 8.2.4 Political Factors
9. Research Interviews 9.1 Interview with Luc Selig, Chief Business Officer at CYTOO 9.1.1 CYTOO’s Definition a Cell-Based Assay, and the Cell-Based Assay Market 9.1.2 The Advantages of CYTOO’s Products and Services 9.1.3 Thoughts on the Competition Within the Cell-Based Assays Market 9.1.4 Revenue Expectations, Company Focus and the Future of the Cell-Based Assay Market 9.1.5 On Challenges for the Industry and Cell-Based Assays vs Animal Models 9.2 Interview with Molecular Devices 9.2.1 Molecular Devices’ Definition of the Market 9.2.2 On Molecular Devices’ Most Well-Known Products, and their Advantages 9.2.3 On the Future of the Cell-Based Assays Market 9.2.4 Opportunities and Challenges for the Market, and the Competition Within it 9.3 Interview with Deborah Moshinsky, President and CEO of Cell Assay Innovations (CAI) 9.3.1 On the Challenges of Developing a Cell-Based Assay 9.3.2 On ClariCELL Technology and its Advantages 9.3.3 Competition in the Cell-Based Assays Market and Future Perspectives
10. Conclusions from the Research and Analysis 10.1 Growth Has Been Driven by Advantages of Cell-Based Assays 10.2 Current Status of the Market and its Growth Drivers 10.3 The Most Dominant National Markets and Emerging Countries 10.4 Future Trends and Technology
List of Figures Figure 1.1 Cell-Based Assays Market Segmented by Application Figure 1.2 Cell-Based Assays Market Segmented by Sector Figure 2.1 Stages of Pre-Clinical Drug Development Figure 3.1 Global Cell-Based Assays Market Forecast: Revenue ($m), 2014-2025 Figure 3.2 Drivers and Restraints for the Cell-Based Assays Market, 2015 Figure 3.3 Cell-Based Assays Market Segments Forecasts: Revenue ($m), 2014-2025 Figure 3.4 Cell-Based Assays Market Segments: Products Forecast- Revenue ($m), 2014-2025 Figure 3.5 Cell-Based Assay Products Overview, 2015 Figure 3.6 Cell-Based Assays Market Segments: Services Forecast- Revenue ($m), 2014-2025 Figure 3.7 Cell-Based Assays Market Application Forecasts: Revenue ($m), 2014-2025 Figure 3.8 Drug Discovery Segment Forecast: Revenue ($m), 2014-2025 Figure 3.9 ADME Segment Forecast: Revenue ($m), 2014-2025 Figure 3.10 Drug Discovery Segment Forecast: Revenue ($m), 2014-2025 Figure 4.1 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2014 Figure 4.2 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2025 Figure 4.3 Global Cell-Based Assays Market, Regional Forecast: Revenues ($m), 2014-2025 Figure 4.4 US Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.5 EU Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.6 EU Market Breakdown by Nation: Revenues ($m), Market Shares (%), 2014 Figure 4.7 EU Market Breakdown by Nation: Revenues ($m), Market Shares (%), 2025 Figure 4.8 EU Market, Top National Forecasts: Revenue ($m), 2014-2025 Figure 4.9 German Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.10 French Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.11 UK Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.12 Spanish Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.13 Italian Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.14 Japanese Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.15 BRIC Countries Breakdown by Nation: Revenues ($m), Market Shares (%), 2014 Figure 4.16 BRIC Countries Breakdown by Nation: Revenues ($m), Market Shares (%), 2025 Figure 4.17 BRIC Countries Breakdown by Nation: Revenues ($m), 2014-2025 Figure 4.18 Chinese Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.19 Indian Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.20 Russian Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 4.21 Brazilian Cell-Based Assays Market Forecast: Revenues ($m), 2014-2025 Figure 5.1 Thermo Fisher Revenue Breakdown by Business Unit: Revenue ($m), 2014 Figure 5.2 PerkinElmer Revenue Breakdown: Revenue ($m), 2014 Figure 5.3 BD Revenue Breakdown: Revenue ($m), 2014 Figure 6.1 Charles River Laboratories Revenue Breakdown: Revenue ($m), 2014 Figure 7.1 Strengths and Weaknesses of the Cell-Based Assay Market, 2015 Figure 7.2 Opportunities and Threats for the Cell-Based Assay Market, 2015
AstraZeneca Axiogenesis Bayer BBC (British Broadcasting Corporation) BD (Becton, Dickinson and Company) BioCity Biocroi Biofocus BioSeek BioVision BMG Labtech CareFusion Corporation Cell Assay Innovations (CAI) Cellartis (Takara Bio) Cellomics Cellular Dynamics Charles River Laboratories Corning Covance CXR Biosciences Cyprotex CYTOO Di Carlo Laboratory DiscoveRx Dr. Reddy’s Laboratories ESI BIO (BioTime) Eurostars Evotec Fisher Scientific Fluofarma ForteBio Foundation Top Institute Pharma GE Healthcare GenCell General Electric (GE) Harlan Laboratories Imagen Biotech InSphero Janssen Japan Institute of Biomedical Research Jubilant Biosys Lead Discovery Centre GmbH Life Technologies Corporation Marin Biologic Laboratories Maxcyte Merck & Co. Molecular Devices OcellO PerkinElmer Pharmaceutical Product Development (PPD) Pharmacyclics PharmaTimes Princeton University Promega ProQinase Quintiles ReNeuron ReproCELL Roche Sanofi Seahorse Bioscience SGS (Société Générale de Surveillance) Solvo SRU Biosystems Swiss Federal Institute of Technology SymCel Syncom The European Lead Factory (ELF) The Innovative Medicines Initiative (IMI) The National Health Service (NHS) The Netherlands Cancer Institute The Scientist Magazine Thermo Electron Thermo Fisher Scientific Trinity College, Dublin Tufts Center for the Study of Drug Development UCB (Union Chimique Belge) UCLA (University of California, Los Angeles) UK Department of Health University of Kyoto University of Oxford University of Zurich US Congress US FDA Vala Sciences WuXi
Download sample pages
Complete the form below to download your free sample pages for Cell-Based Assays: World Industry and Market Prospects 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Cell-Based Assays: World Industry and Market Prospects 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
